ME Therapeutics Holdings Cash Flow Statement

Financials in millions CAD. Fiscal year is September - August.

Millions CAD. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	May '25 May 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022
Net Income	-1.17	-1.29	-6.52	-0.15
Depreciation & Amortization	0.06	0	0	0
Stock-Based Compensation	0.34	0.7	0.62	0.01
Other Operating Activities	0.01	-	5.55	0.01
Change in Accounts Payable	0.03	-0.06	0.06	-0
Change in Other Net Operating Assets	-0.04	-0	-0.02	-0.01
Operating Cash Flow	-0.77	-0.66	-0.3	-0.14
Cash Acquisitions	-	-	0.76	-
Investing Cash Flow	-0.24	-	0.76	-
Short-Term Debt Issued	-	-	-	0.14
Total Debt Issued	-	-	-	0.14
Short-Term Debt Repaid	-	-0.04	-	-
Total Debt Repaid	-0.04	-0.04	-	-
Net Debt Issued (Repaid)	-0.04	-0.04	-	0.14
Issuance of Common Stock	1.05	1.56	0.12	-
Other Financing Activities	-0.01	-0.01	-	-
Financing Cash Flow	1	1.51	0.12	0.14
Net Cash Flow	-0	0.85	0.57	0
Levered Free Cash Flow	-0.53	-0.22	0.07	-
Unlevered Free Cash Flow	-0.52	-0.22	0.08	-
Change in Net Working Capital	0.01	0.06	-0.07	-

Updated Jan 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.